Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has received an average recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $27.22.
A number of equities analysts have commented on the stock. Needham & Company LLC boosted their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 28th. HC Wainwright boosted their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th.
View Our Latest Report on PCRX
Institutional Investors Weigh In On Pacira BioSciences
Pacira BioSciences Price Performance
NASDAQ:PCRX opened at $22.87 on Monday. The firm has a market cap of $1.06 billion, a PE ratio of -11.27 and a beta of 0.86. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $23.96 and its two-hundred day moving average price is $19.31.
About Pacira BioSciences
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Further Reading
- Five stocks we like better than Pacira BioSciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How to Build the Ultimate Everything ETF Portfolio
- Energy and Oil Stocks Explained
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.